Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% | +0.14% | +29.68% |
2023 | Nestle Reportedly May Sell Peanut Allergy Therapy to Stallergenes | CI |
2023 | Stallergenes Greer Ltd Initiates European Paediatric Phase III Study with Staloral Birch | CI |
Valuation
Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|---|
Capitalization 1 | 608.6 | 759.5 | 558.6 | 724 | 724 | 724 |
Enterprise Value (EV) 1 | 560.5 | 727.2 | 503.4 | 764.2 | 961.3 | 973.1 |
P/E ratio | -10.1 x | -77 x | 43.8 x | 21.7 x | 21.5 x | 11.9 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 3.27 x | 2.92 x | 2.02 x | 2.39 x | 2.38 x | 2.21 x |
EV / Revenue | 3.01 x | 2.79 x | 1.82 x | 2.53 x | 3.16 x | 2.97 x |
EV / EBITDA | -7.78 x | 54.1 x | 13.6 x | 11.5 x | 11.5 x | 9.46 x |
EV / FCF | -8.52 x | -50.4 x | 27.1 x | 28.6 x | 20.3 x | 18.5 x |
FCF Yield | -11.7% | -1.98% | 3.69% | 3.5% | 4.93% | 5.42% |
Price to Book | 1.25 x | 1.7 x | 1.19 x | 1.93 x | 5.55 x | 6.04 x |
Nbr of stocks (in thousands) | 19,697 | 19,722 | 19,737 | 19,728 | 19,728 | 19,728 |
Reference price 2 | 30.90 | 38.51 | 28.30 | 36.70 | 36.70 | 36.70 |
Announcement Date | 4/28/17 | 4/16/18 | 3/21/19 | 10/26/20 | 10/14/21 | 5/6/22 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|---|
Net sales 1 | 186.4 | 260.2 | 277.1 | 302.5 | 303.9 | 328.1 |
EBITDA 1 | -72.04 | 13.45 | 36.89 | 66.18 | 83.75 | 102.8 |
EBIT 1 | -92.54 | -5.21 | 20.88 | 50.23 | 67.6 | 88.77 |
Operating Margin | -49.65% | -2% | 7.54% | 16.6% | 22.24% | 27.06% |
Earnings before Tax (EBT) 1 | -96.3 | -7.726 | 16.67 | 45.01 | 56.89 | 85.75 |
Net income 1 | -60.52 | -9.871 | 12.76 | 33.3 | 33.7 | 60.67 |
Net margin | -32.47% | -3.79% | 4.61% | 11.01% | 11.09% | 18.49% |
EPS 2 | -3.070 | -0.5001 | 0.6465 | 1.688 | 1.708 | 3.084 |
Free Cash Flow 1 | -65.77 | -14.42 | 18.59 | 26.72 | 47.35 | 52.74 |
FCF margin | -35.29% | -5.54% | 6.71% | 8.83% | 15.58% | 16.08% |
FCF Conversion (EBITDA) | - | - | 50.4% | 40.38% | 56.54% | 51.3% |
FCF Conversion (Net income) | - | - | 145.73% | 80.25% | 140.49% | 86.93% |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 4/28/17 | 4/16/18 | 3/21/19 | 10/26/20 | 10/14/21 | 5/6/22 |
Balance Sheet Analysis
Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | 40.2 | 237 | 249 |
Net Cash position 1 | 48.2 | 32.3 | 55.2 | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | 0.6076 x | 2.833 x | 2.422 x |
Free Cash Flow 1 | -65.8 | -14.4 | 18.6 | 26.7 | 47.4 | 52.7 |
ROE (net income / shareholders' equity) | -11.8% | -2.11% | 2.78% | 7.86% | 13.3% | 48.6% |
ROA (Net income/ Total Assets) | -8.79% | -0.56% | 2.34% | 5.47% | 7.7% | 10.4% |
Assets 1 | 688.6 | 1,774 | 544.8 | 609 | 438 | 583 |
Book Value Per Share 2 | 24.80 | 22.70 | 23.90 | 19.00 | 6.610 | 6.070 |
Cash Flow per Share 2 | 3.610 | 2.580 | 3.750 | 3.210 | 3.210 | 4.300 |
Capex 1 | 22 | 12.6 | 24.9 | 16 | 12.7 | 16.8 |
Capex / Sales | 11.81% | 4.86% | 8.97% | 5.29% | 4.19% | 5.11% |
Announcement Date | 4/28/17 | 4/16/18 | 3/21/19 | 10/26/20 | 10/14/21 | 5/6/22 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+29.68% | 0 | |
+5.48% | 71.19B | |
+12.55% | 9.3B | |
-13.75% | 5.01B | |
+42.38% | 4.47B | |
+4.51% | 3.96B | |
-19.05% | 2.41B | |
-28.72% | 2.23B | |
+11.13% | 2.02B | |
+6.53% | 1.69B |
- Stock Market
- Equities
- STAGR Stock
- Financials Stallergenes Greer